In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Private Bid For KCI Signals Growth In Wound Care

Executive Summary

Historically, wound care has been a nice tuck-in business for both large medical device and pharmaceutical companies. But that dynamic appears to be changing as advanced technologies are developed that make this sector more attractive as a growth business, evidenced by the large number of recent deals and consolidation going on in this market. The latest example of this trend is the proposed $6.3 billion deal to make publicly traded Kinetic Concepts a privately held company.

You may also be interested in...



Maximizing An Innovative Device Launch: Going Slow To Go Fast

Contrary to conventional wisdom, a gradual product rollout, as opposed to a full-court press, may be the best way for device companies to generate maximum value from innovative products.

Spiracur Inc.

Indicated for many types of acute and chronic wounds, negative pressure wound therapy kicks off many mechanisms useful in wound healing. However, the devices aren't used in all patients for whom they're indicated for reasons that have to do with inconvenience, logistics and quality of life. Spiracur offers the same negative pressure therapy in a small, entirely mechanical, tether-free disposable device that replaces the cumbersome electric pumps that dominate the market today.

Patient-Centric Devices Promise Cost-Efficient Advanced Wound Care

The treatment of chronic wounds is challenging, not only because of the underlying biology, but also because of more practical considerations: fragmentation in the care settings, the logistics of delivering products to patients, and the costs of chronic care. Next generation advanced wound care companies are engineering solutions to these problems.

Related Content

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

IV003674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel